Iconic Therapeutics focuses on developing innovative therapies targeting Tissue Factor (TF), a protein implicated in various disease processes. Their pipeline includes monoclonal antibodies specifically designed to address the mechanisms of diseases such as acute and chronic inflammatory conditions, including acute lung injury and inflammatory bowel disease. Additionally, the company is exploring promising applications in ophthalmology, particularly for serious diseases like age-related macular degeneration (AMD) and diabetic retinopathy. Their oncology program, in partnership with Exelixis, aims to leverage the overexpression of TF in tumors to facilitate targeted treatment strategies.

The company's lead product candidates include antibody-drug conjugates that target TF, which have shown potential in preclinical studies for treating solid tumors without adversely affecting blood clotting. Iconic's research emphasizes the importance of TF in both cancer progression and inflammatory diseases, positioning their therapies as potentially transformative in these areas. Their ongoing collaborations and clinical trials underscore a commitment to advancing the understanding and treatment of conditions associated with TF, aiming to deliver best-in-class therapeutic options.

United States

Iconic Therapeutics is a biopharmaceutical company that focuses on developing therapies targeting Tissue Factor in angiogenesis, inflammation, and malignancies.

Iconic Therapeutics

Company Details